On July 29, 2020 Akoya Biosciences, Inc., The Spatial Biology Company, reported a collaboration with UCSF Helen Diller Family Comprehensive Cancer Center (Press release, Akoya Biosciences, JUL 29, 2020, View Source [SID1234562522]). Scientists at UCSF Helen Diller Family Comprehensive Cancer Center have chosen Akoya’s Phenoptics multiplex immunofluorescence platform for developing predictive and prognostic biomarkers, particularly for use in selecting the most effective neoadjuvant and adjuvant immunotherapies for patients with early breast cancer. Click here to view a multimedia version of the press release, including media-ready images, downloadable resources, and more.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At UCSF, this collaboration will be led by Michael Campbell, PhD, and Laura Esserman, MD, MBA. Dr. Campbell is an immunologist who has worked in partnership with Dr. Esserman to better understand how to optimize immunotherapy. He is driving the work on the Phenoptics platform to develop predictors of response to the immuno-oncology drug combinations, and to use these insights to develop more effective combinations. Together they are working both on high risk invasive breast cancer and high-risk ductal carcinoma in situ (DCIS).
Dr. Esserman is a professor in the departments of Surgery and Radiology who co-leads the breast oncology program at the UCSF Helen Diller Family Comprehensive Cancer Center, and is the Principal Investigator of the I-SPY Trials, sponsored by the Quantum Leap Healthcare Collaborative. Following extensive evaluation of biomarker testing methods, Dr. Esserman and her team have standardized biomarker discovery and development efforts on the Phenoptics platform to measure as many as six markers at a time on a single pathology slide using multiplex immunofluorescence. The Phenoptics platform is the chosen platform for the I-SPY Trials.
"There is a clear need for biomarkers to guide both the choice and assessment of immune targeted combinations for high risk early-stage cancers, where opportunities for cure are much greater," said Dr. Esserman. "We believe that multiplexed immunofluorescence will lead to robust, predictive assays, because it enables better understanding of the cell-level biology underlying disease progression and response to therapy, by revealing the spatial arrangements and interactions of cells in the tumor microenvironment."
Immunotherapies harness the immune system to fight cancer and are increasingly being used in the early high-risk setting. The partnership’s goals are to make these therapies more effective and to understand the immune response, key to making them work for more patients. There is an urgent need for biomarkers that more accurately predict which patients will respond to a particular therapy. Multiplex immunofluorescence preserves critical spatial data about cell proximity and interaction in the tumor microenvironment, with the potential to provide higher predictive power compared to other biomarker approaches. Akoya’s Phenoptics platform provides an end-to-end solution for discovery research and clinical trials with the reproducibility, sensitivity and throughput needed to develop new biomarkers and has become the standard for biomarker-based clinical trials and translational research.
Cliff Hoyt, Vice President of Translational and Scientific Affairs at Akoya, commented: "Dr. Esserman is well known for her substantial achievements in characterizing the tumor microenvironment and treating breast cancers and it is an honor for our team to collaborate with her lab. With Dr. Esserman’s focus on practical and effective steps to improve drug development and the standard of care, we believe that this collaboration will have a real impact on patient treatment in the coming years."